17:57 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

Polyphor reports Phase Ib data for breast cancer candidate

Polyphor Ltd. (Allschwill, Switzerland) reported data from an open-label, dose-escalation Phase Ib trial in 54 women with previously treated HER2-negative, CXC chemokine receptor 4 (CXCR4; NPY3R)-positive metastatic breast cancer showing that IV balixafortide (POL6326) plus...
08:00 , Dec 4, 2014 |  BC Innovations  |  Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc.'s Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease. Last year,...
07:00 , Sep 17, 2012 |  BioCentury  |  Product Development

Excited about cycling

New synthesis and screening technologies and the allure of access to previously undruggable targets are driving an explosion of new company formation and deal-making around macrocycles and constrained peptides. While it remains to be seen whether...
07:00 , Sep 4, 2008 |  BC Innovations  |  Targets & Mechanisms

CXCR4 for CNS Infections

The purpose of the blood-brain barrier is to limit trafficking of leukocytes into the immune-privileged CNS. However, this becomes an undesirable trait when trying to clear acute CNS infections.1 Indeed, one component of the body's...
07:00 , Jul 14, 2008 |  BC Week In Review  |  Clinical News

POL6326: Phase I data

In a U.K. Phase I trial in 74 healthy volunteers, POL6326 was well tolerated. The compound also mobilized HSCs into the bloodstream. Polyphor Ltd., Allschwil, Switzerland   Product: POL6326   Business: Cancer   Molecular target: CXC...